Sigma Planning Corp raised its position in Bristol-Myers Squibb Co (NYSE:BMY) by 9.0% in the third quarter, Holdings Channel reports. The fund owned 34,854 shares of the biopharmaceutical company’s stock after purchasing an additional 2,877 shares during the quarter. Sigma Planning Corp’s holdings in Bristol-Myers Squibb were worth $2,222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently made changes to their positions in BMY. Tradewinds Capital Management LLC lifted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the last quarter. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at $111,000. Massey Quick Simon & CO. LLC lifted its stake in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the last quarter. Finally, BDO Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at $123,000. Hedge funds and other institutional investors own 69.74% of the company’s stock.
Shares of Bristol-Myers Squibb Co (BMY) opened at $62.81 on Tuesday. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The firm has a market cap of $102,800.00, a PE ratio of 24.73, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s payout ratio is 62.99%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
A number of analysts have commented on BMY shares. UBS Group reiterated a “buy” rating and issued a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Finally, Citigroup raised their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $65.11.
ILLEGAL ACTIVITY NOTICE: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://baseballnewssource.com/markets/bristol-myers-squibb-co-bmy-holdings-increased-by-sigma-planning-corp/1838785.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with our FREE daily email newsletter.